Zeria Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4559.T

Zeria Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 29, 2025: 12.41

Zeria Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) is 12.41 on January 29, 2025, a -5.28% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Zeria Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 14.38 on February 05, 2024, which is 15.92% above the current Price to Earnings Ratio (P/E).
  • Zeria Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 10.61 on May 29, 2024, which is -14.47% below the current Price to Earnings Ratio (P/E).
  • Zeria Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 12.60.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 4559.T

Zeria Pharmaceutical Co., Ltd.

CEO Mr. Sachiaki Ibe
IPO Date Jan. 1, 2001
Location Japan
Headquarters 10-11 Nihonbashi Kobuna-cho
Employees 1,777
Sector Health Care
Industries
Description

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 27.46

-1.12%

4540.T

Tsumura & Co.

USD 29.37

0.29%

4551.T

Torii Pharmaceutical Co., Ltd.

USD 32.26

-0.24%

4547.T

Kissei Pharmaceutical Co., Ltd.

USD 25.53

-0.97%

4516.T

Nippon Shinyaku Co., Ltd.

USD 23.82

-0.94%

StockViz Staff

January 30, 2025

Any question? Send us an email